BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2290 related articles for article (PubMed ID: 24211739)

  • 1. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
    Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
    J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
    Liu L; Yang X; Li NF; Lin L; Luo H
    Cell Cycle; 2019 Nov; 18(21):2939-2953. PubMed ID: 31522588
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
    Yang F; Lv LZ; Cai QC; Jiang Y
    World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2.
    Wang G; Sun Y; He Y; Ji C; Hu B; Sun Y
    Genet Test Mol Biomarkers; 2015 Jan; 19(1):30-6. PubMed ID: 25494962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-1297 regulates hepatocellular carcinoma cell proliferation and apoptosis by targeting EZH2.
    Liu F; He Y; Shu R; Wang S
    Int J Clin Exp Pathol; 2015; 8(5):4972-80. PubMed ID: 26191190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
    Zheng F; Liao YJ; Cai MY; Liu YH; Liu TH; Chen SP; Bian XW; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
    Gut; 2012 Feb; 61(2):278-89. PubMed ID: 21672940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targeting BMI1.
    Wu WR; Sun H; Zhang R; Yu XH; Shi XD; Zhu MS; Zeng H; Yan LX; Xu LB; Liu C
    Oncotarget; 2016 Apr; 7(14):18684-93. PubMed ID: 26919246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-548a-5p promotes proliferation and inhibits apoptosis in hepatocellular carcinoma cells by targeting Tg737.
    Zhao G; Wang T; Huang QK; Pu M; Sun W; Zhang ZC; Ling R; Tao KS
    World J Gastroenterol; 2016 Jun; 22(23):5364-73. PubMed ID: 27340352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
    Xia H; Ooi LL; Hui KM
    PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma.
    Huang D; Wang X; Zhuang C; Shi W; Liu M; Tu Q; Zhang D; Hu L
    Oncol Rep; 2016 Feb; 35(2):1083-90. PubMed ID: 26718325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis.
    Feng Y; Wei G; Zhang L; Zhou H; Wang W; Guo P; Cheng C; Ji L; Cai Q; Feng Y; Tu H
    Bioengineered; 2021 Dec; 12(1):8217-8232. PubMed ID: 34596006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
    Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
    Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
    Huang B; Huang M; Li Q
    Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-340 impedes the progression of laryngeal squamous cell carcinoma by targeting EZH2.
    Yu W; Zhang G; Lu B; Li J; Wu Z; Ma H; Wang H; Lian R
    Gene; 2016 Feb; 577(2):193-201. PubMed ID: 26656176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/β-catenin signaling pathway.
    Zhang JJ; Chen JT; Hua L; Yao KH; Wang CY
    Biomed Pharmacother; 2017 Jan; 85():472-478. PubMed ID: 27890434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
    Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
    J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin.
    Chen Y; Lin MC; Yao H; Wang H; Zhang AQ; Yu J; Hui CK; Lau GK; He ML; Sung J; Kung HF
    Hepatology; 2007 Jul; 46(1):200-8. PubMed ID: 17596871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
    Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
    J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 115.